Yixintang Pharmaceutical Group Co., Ltd. (SHE:002727)
China flag China · Delayed Price · Currency is CNY
13.48
-0.26 (-1.89%)
Nov 18, 2026, 3:04 PM CST

SHE:002727 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
16,43316,73617,46216,87717,12414,275
Other Revenue
599.91599.91538.72503.73307.42312.21
17,03317,33618,00017,38017,43214,587
Revenue Growth
-2.18%-3.69%3.57%-0.29%19.50%15.26%
Cost of Revenue
11,53211,82912,42811,79811,4869,320
Gross Profit
5,5015,5075,5735,5825,9465,267
Selling, General & Admin
4,8554,9415,1664,6634,5124,087
Research & Development
6.5310.599.7110.28.745.39
Other Operating Expenses
-16.07-11.167.6732.6217.17-13.93
Operating Expenses
4,8714,9785,1904,7394,6284,082
Operating Income
630.09528.4383.26843.931,3181,185
Interest Expense
-114.12-133.22-146.04-135.34-93.72-136.22
Interest & Investment Income
14.4221.0247.0486.487.4953.52
Currency Exchange Gain (Loss)
----0.23-0.09
Other Non Operating Income (Expenses)
2.74-4.37-76.25-93.761.48-4.53
EBT Excluding Unusual Items
533.12411.83208701.321,2331,098
Impairment of Goodwill
-21.44-21.44-26.77-11.65-12.29-10.97
Gain (Loss) on Sale of Investments
-3.84-7.1-3.43-8.36-5.72-5.77
Gain (Loss) on Sale of Assets
9.828.793.181.12-13.83-13.41
Asset Writedown
18.25-3.29-2.17-2.93-13.85-2.71
Other Unusual Items
17.817.828.523.0747.4831.29
Pretax Income
553.72406.59207.31702.561,2351,097
Income Tax Expense
178.19134.8997.02142.15222179.32
Earnings From Continuing Operations
375.52271.71110.29560.411,013917.21
Minority Interest in Earnings
0.34-8.273.85-10.97-2.984.38
Net Income
375.86263.43114.14549.441,010921.58
Net Income to Common
375.86263.43114.14549.441,010921.58
Net Income Growth
316.57%130.80%-79.23%-45.60%9.59%16.66%
Shares Outstanding (Basic)
568576592597593590
Shares Outstanding (Diluted)
568576592597595592
Shares Change
-2.86%-2.70%-0.76%0.27%0.50%3.32%
EPS (Basic)
0.660.460.190.921.701.56
EPS (Diluted)
0.660.460.190.921.701.56
EPS Growth
328.84%137.21%-79.07%-45.75%9.05%12.91%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
1,8371,3551,4661,8622,1481,400
Free Cash Flow Per Share
3.242.352.483.123.612.36
Dividend Per Share
0.2000.4000.3000.4000.4000.300
Dividend Growth
-60.00%33.33%-25.00%0%33.33%0%
Gross Margin
32.30%31.77%30.96%32.12%34.11%36.11%
Operating Margin
3.70%3.05%2.13%4.86%7.56%8.13%
Profit Margin
2.21%1.52%0.63%3.16%5.79%6.32%
Free Cash Flow Margin
10.79%7.82%8.14%10.71%12.32%9.60%
EBITDA
729.3636.54503.29968.591,4321,283
EBITDA Margin
4.28%3.67%2.80%5.57%8.22%8.80%
D&A For EBITDA
99.22108.14120.03124.66114.4698.08
EBIT
630.09528.4383.26843.931,3181,185
EBIT Margin
3.70%3.05%2.13%4.86%7.56%8.13%
Effective Tax Rate
32.18%33.17%46.80%20.23%17.98%16.35%
Revenue as Reported
17,03317,33618,00017,38017,43214,587
Advertising Expenses
-50.1362.949.5549.2842.16